CSRHub is the world’s largest CSR (corporate social responsibility) and sustainability ratings and information database.

Ono Pharmaceutical Company Limited

Subscribe to see all available data

Ono Pharmaceutical Company Limited is a developer and manufacturer of pharmaceuticals and related products. Ono Pharmaceutical produces medicines and healthcare products for customers with a range of illnesses. The Company, based in Osaka, Japan, has operations throughout Japan as well as in Europe and the United States.

Ticker: 4528-TO ISIN: JP3197600004
Address: 1-8-2, Kutaro-cho Chuo-ku , Japan , Osaka-shi , OSK , 541-8564 Website: Ono Pharmaceutical Company Limited
Phone #: 81-6-62635670 CSR Web Area: SUBSCRIPTION INFO

Basic Corporate Social Responsibility (CSR) Ratings

  Overall Community Employees Environment Governance
Ono Pharmaceutical Company Limited 48 47 44 55 44
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
All company average 55 55 56 58 52
Japan
SUBSCRIPTION INFO

Percentile Rankings

Rankings are in percentile terms, compared to other companies in the same industry and country Overall Community Employees Environment Governance
Ono Pharmaceutical Company Limited 13% 16% 10% 37% 20%
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
Japan
SUBSCRIPTION INFO
Special Issues:

Ratings History

Only subscribers can interact with the graph.

More CSR Rating Details

  Community Employees
Community Dev & Philanthropy Product Human Rights & Supply Chain Compensation & Benefits Diversity & Labor Rights Training, Health & Safety
Ono Pharmaceutical Company Limited
SUBSCRIPTION INFO
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
All company average 53 54 55 58 55 55
Japan
SUBSCRIPTION INFO

Environment Governance
Energy & Climate Change Environmant Policy & Reporting Resource Management Board Leadership Ethics Transparency & Reporting
Ono Pharmaceutical Company Limited
SUBSCRIPTION INFO
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
All company average 57 58 57 50 55 51
Japan
SUBSCRIPTION INFO

Percentile rankings

Rankings are in percentile terms, compared to other companies in the same industry and country Community Employees
Community Dev & Philantrophy Product Human Rights & Supply Chain Compensation & Benefits Diversity & Labor Rights Training, Health & Safety
Ono Pharmaceutical Company Limited 4% 61% 18% 8% 11% 34%
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
Japan
SUBSCRIPTION INFO

Environment Governance
Energy & Climate Change Environment Policy & Reporting Resource Management Board Leadership Ethics Transparency & Reporting
Ono Pharmaceutical Company Limited 44% 55% 21% 13% 31% 43%
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
Japan
SUBSCRIPTION INFO

0 Special Issues Affect This Company (see a list of issues here)

# of Sources
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
Overall database
Japan
SUBSCRIPTION INFO

CSRHub Has 15 Data Sources (10 Are Currently Active) for This Company

= sources impacting the current ratings
= sources not impacting the current ratings, but included in earlier ratings for this company
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO

Original Data Values

(unsubscribed users can see the list, subscribers can see the data details for most sources)

Data source name

Data source element name Minimum value Value provided by datasource Maximum value Data description
Brand Finance 2011-12
SUBSCRIPTION INFO
Brand Value / Enterprise Value (%) -48.164682123 0.029 316.6056 NA
Brand Value 2012 19.6075 NA
BSI 50 59.6864 88.4717 NA
Domicile JAPAN NA
Enterprise Value NA 1759.9655 NA NA
Reviewed ? No response NA
Sector Consumer, Non-cyclical NA
SUBSCRIPTION INFO
8.8a. Please provide the emissions in metric tonnes CO2e 0.05 NA 13638000
0.4. Currency selection Please select the currency in which you would like to submit your response. All financial information contained in the response should be in this currency. JPY(¥)
0.6. Modules NA As part of the Investor CDP information request, electric utilities, companies with electric utility activities or assets, companies in the automobile or auto component manufacture sectors and companies in the oil and gas industry should complete suppleme
1. Attachments NA NA NA
1. Further Information NA 上記金銭的インセンティブの回答は当社の城東工場とフジヤマ工場の全ての従業員を対象に運営がなされています。上記非金銭的インセンティブの回答は、水無瀬研究所において、全社員を対象に、表彰と洋菓子をインセンティブとして、標語を募集して優秀賞を選出し、表彰するとともに、副賞(洋菓子)を贈呈しています。 NA
1.1. Where is the highest level of direct responsibility for climate change within your company? No individual or committee with overall responsibility for climate change Individual/Sub-set of the Board or other committee appointed by the Board Individual/Sub-set of the Board or other committee appointed by the Board
1.2. Do you provide incentives for the management of climate change issues, including the attainment of targets? No Yes Yes
11. Attachments NA NA NA
11. Further Information NA NA NA
11.1. What percentage of your total operational spend in the reporting year was on energy? More than 0% but less than or equal to 5% More than 0% but less than or equal to 5% More than 95% but less than or equal to 100%
12. Attachments NA
12. Further Information 総量が原子力発電所停止による電力会社公表のCO2排出係数が悪化したためGHG量が30%増加しました。売上高、従業員数、床面積が全て前年度並みだったので、原単位当たりの数値の推移も総量の推移と同水準でした。
12.1. How do your absolute emissions (Scope 1 and 2 combined) for the reporting year compare to the previous year? Increased
12.1a Reason of change Emissions reduction activities, Divestment, Acquisitions, Mergers, Change in output, Change in methodology, Change in boundary, Change in physical operating conditions, Unidentified, Other
14. Attachments NA NA NA
14. Further Information NA 排出量取引制度に参加する誘因が無いと考えています。地道な省エネ活動こそが地球温暖化防止に繋がると確信しています。 NA
14.1. Do you participate in any emission trading schemes? No, and we do not currently anticipate doing so in the next two years No, and we do not currently anticipate doing so in the next 2 years Yes
14.1b. What is your strategy for complying with the schemes in which you participate or anticipate participating? NA
14.2. Has your company originated any project-based carbon credits or purchased any within the reporting period? No No Yes
2. Attachments NA NA NA
2. Further Information NA 研究所では、省エネ法の下、定期報告書や中長期計画の策定、削減推進を行っていますし、温対法の下、環境自主行動計画の策定、定期報告書提出、削減推進を行っています。 NA
2.1. Please select the option that best describes your risk management procedures with regard to climate change risks and opportunities NA Integrated into multi-disciplinary company wide risk management processes NA
2.1a. Please provide further details (see guidance) NA 気候変動リスク管理については、環境自主行動計画やBCPマニュアルの策定、中長期の設備投資計画による温室効果ガス削減計画を立案し取り組んでいる。計画は燃料転換など削減効果の大きいものから優先的に実行しており、削減結果はCSR委員会(環境委員会)にて報告を行っている。CO2削減目標については2020年のCO2排出量を2005年排出量に対し23%削減するよう目標をたて、CSR委員会に於いてモニタリングしており、CSR委員会の議事録については取締役全員に回覧している。 NA
2.2. Is climate change integrated into your business strategy? No Yes Yes
2.2a. Please describe the process and outcomes (see guidance) NA 環境自主行動計画に基づいて各事業所に於いては、環境委員会や安全衛生委員会等で、温暖化防止に向けた社員への啓蒙活動を行うとともに、全社的にはCSR委員会にて環境全般についての方針決定を行っている。 NA
2.2b. Please explain why not NA NA NA
2.3. Do you engage in activities that could either directly or indirectly influence policy on climate change through any of the following? (tick all that apply) Yes
2.3a. Please explain (i) the engagement process and (ii) actions you are advocating NA NA NA
2.3b. Are you on the Board of any trade associations or provide funding beyond membership? Yes
2.3d. Do you publically disclose a list of all the research organizations that you fund? NA
3. Attachments NA NA NA
3. Further Information NA 規制を満たせるよう従業員のエンゲージメントを徹底しています。 NA
3.1. Did you have an emissions reduction target that was active (ongoing or reached completion) in the reporting year? No Absolute target Absolute and intensity targets
3.1e. Please explain (i) why not; and (ii) forecast how your emissions will change over the next five years NA NA NA
3.2. Does the use of your goods and/or services directly enable GHG emissions to be avoided by a third party? No No Yes
3.2a. Please provide details (see guidance) NA NA NA
3.3c Number of methods used to drive investment in emissions reduction activities. 0 1 13 Number of methods used to drive investment in emissions reduction activities.
3.3c. What methods do you use to drive investment in emissions reduction activities? NA Compliance with regulatory requirements/standards NA
4. Attachments NA
4. Have you published information about your company’s response to climate change and GHG emissions performance for this reporting year in other places than in your CDP response? - Further Information 環境社会報告書で26頁あります。以下に添付します。
4.1. Have you published information about your company’s response to climate change and GHG emissions performance for this reporting year in other places than in your CDP response? 0 The number of corporate annual reports and voluntary publications (complete and/or underway) made about the company’s response to climate change and GHG emissions performance
5. Attachments NA https://www.cdproject.net/sites/2013/09/13909/Investor CDP 2013/Shared Documents/Attachments/InvestorCDP2013/5.ClimateChangeRisks/bcp20120920.ppt NA
5. Further Information NA 当社のBCPを下記に添付いたします。 NA
5.1. Have you identified any climate change risks (current or future) that have potential to generate a substantive change in your business operations, revenue or expenditure? Tick all that apply NA Risks driven by changes in regulation; Risks driven by changes in physical climate parameters NA
5.1a. Climate change risks driven by changes in regulation Yes
5.1c. Climate change risks driven by change in physical climate parameters Yes
5.1d. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk; and (iii) the costs associated with these actions NA (i) 年間売上1500億円全体に影響が出る。(ⅱ)各種機器(ボイラー等)などの日常及び定期点検を計画的に実施し、リスク影響を受けない様に管理している。関連設備が設置されている期間は毎年継続して行く。 (ⅲ)計画的な運用コストであり、関連設備が設置されている期間は毎年継続して行く。 NA
5.1f. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk; (iii) the costs associated with these actions NA NA NA
5.1g. Please explain why you do not consider your company to be exposed to risks driven by changes in regulation that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
5.1h. Please explain why you do not consider your company to be exposed to risks driven by physical climate parameters that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
5.1i. Please explain why you do not consider your company to be exposed to risks driven by changes in other climate-related developments that have the potential to generate a substantive change in your business operations, revenue or expenditure NA 製薬企業は生命関連産業であることから、単品では赤字でも必要な薬剤は安定供給する義務があります。そのために、当社においても製品・商品在庫を十分に保有していますし、当社が定義したBCP(事業継続計画)においても、安定供給を第一に定義しています。具体的には、東日本と西日本に工場と物流センターを各1サイトずつ、合計4サイト保持していて、東日本か西日本のどちらかに壊滅的な災害等の事象が発生して機能停止になったとしても、被害を受けなかった側から供給できるようにしているからです。想定できる規制・物理的リスクに対応してい NA
6. Attachments NA NA NA
6. Further Information NA 前項でBCPは添付しました。また規制と物理の財務影響は合計金額となっています。 NA
6.1. Have you identified any climate change opportunities (current or future) that have the potential to generate a substantive change in your business operations, revenue or expenditure? Tick all that apply NA Opportunities driven by changes in regulation; Opportunities driven by changes in physical climate parameters NA
6.1. Have you identified any climate change opportunities (current or future) that have the potential to generate a substantive change in your business operations, revenue or expenditure? -Transparency Yes
6.1a Identified climate change opportunities that are driven by changes in regulation? NA Yes NA
6.1c. Please describe the opportunities that are driven by changes in physical climate parameters Yes
6.1f. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity; (iii) the costs associated with these actions NA NA NA
6.1g. Please explain why you do not consider your company to be exposed to opportunities driven by changes in regulation that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
6.1h. Please explain why you do not consider your company to be exposed to opportunities driven by physical climate parameters that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
6.1i. Please explain why you do not consider your company to be exposed to opportunities driven by changes in other climate-related developments that have the potential to generate a substantive change in your business operations, revenue or expenditure NA 製薬企業は生命関連産業であることから、単品では赤字でも必要な薬剤は安定供給する義務があります。そのために、当社においても製品・商品在庫を十分に保有していますし、当社が定義したBCP(事業継続計画)においても、安定供給を第一に定義しています。具体的には、東日本と西日本に工場と物流センターを各1サイトずつ、合計4サイト保持していて、東日本か西日本のどちらかに壊滅的な災害等の事象が発生して機能停止になったとしても、被害を受けなかった側から供給できるようにしているからです。想定できる規制・物理的リスクに対応してい NA
7. Attachments NA https://www.cdproject.net/sites/2013/09/13909/Investor CDP 2013/Shared Documents/Attachments/InvestorCDP2013/7.EmissionsMethodology/燃料別換算表.xls NA
7. Further Information NA 使用量は小さいが、都市ガス、軽油、灯油、プロパンガス、電気、ガソリンの使用もある。 NA
8.1. Please select the boundary you are using for your Scope 1 and 2 greenhouse gas inventory NA Financial control NA Boundary used for Scope 1 and 2 greenhouse gas inventory during 2011-2012/01 Jan 2012 - 31 Dec 2012 reporting period
8.2. Please provide your gross global Scope 1 emissions figure in metric tonnes CO2e 11779 Gross global Scope 1 emissions figure in metric tonnes CO2e for 2011 - 2012/01 Jan 2012 - 31 Dec 2012 reporting period
8.3. Please provide your gross global Scope 2 emissions figures in metric tonnes CO2e 20224
8.4. Are there are any sources (e.g. facilities, specific GHGs, activities, geographies, etc.) of Scope 1 and Scope 2 emissions which are not included in your disclosure? NA Yes NA Proportion of Scope 1 emissions that are verified/assured for 2011 - 2012/01 Jan 2012 - 31 Dec 2012 reporting period
2013 Performance Band E C A NA
2013 Score 0 65 100 NA
0. Attachments NA https://www.cdproject.net/sites/2013/09/13909/Investor CDP 2013/Shared Documents/Attachments/InvestorCDP2013/Introduction/小野薬品有価証券報告書2013年3月期.pdf NA If you have not been presented with a sector module that you consider would be appropriate for your company to answer, please select the module below. If you wish to view the questions first, please see https://www.cdproject.net/en-US/Programmes/Pages/Mor
0. Further Information NA NA NA If you are in these sectors (according to the Global Industry Classification Standard (GICS)), the corresponding sector modules will be marked as default options to your information request. If you want to query your classification, please email respond@c
0.1. Introduction - Please give a general description and introduction to your organization. NA 【会社名】 小野薬品工業株式会社【英訳名】 ONO PHARMACEUTICAL CO., LTD.【代表者の役職氏名】 代表取締役社長 相 良 暁【本店の所在の場所】 大阪市中央区道修町二丁目1番5号 医薬品の製造販売を業としています。財務の概要は下記の通りです。 回次 第60期 第61期 第62期 第63期 第64期 決算年月 平成20年3月 平成21年3月 平成22年3月 平成23年3月 平成24年3月 売上高 (百万円) 145,897 136,556 135,986 135, NA
SUBSCRIPTION INFO
ceo:numberOfRatings 1 0 4026 The number of ratings of the CEO
ceo:pctApprove 0 0 100 Percent of ratings of the CEO that were approving
ceo:title NA The title of the company's CEO
employer:numberOfRatings 1 0 6549 The number of Glassdoor users who have rated this company as a place to work.
Glassdoor Employer Ratings 1 0 5 The Top Companies for Work-Life Balance list is based on employee feedback shared in company reviews on Glassdoor.
SUBSCRIPTION INFO
Date Added To Sr List NA 41446.1667 NA Date added to the GRI list.
Guidelines NA GRI - G3 NA This field indicates which version of the GRI Guidelines is used for the reporting. As of publication year 2009, GRI only includes reporting that makes use of the G3 Guidelines, which were released in October 2006.
Integrated No Yes Yes GRI currently has two classifications for defining organization size: 'SME' and 'Large'. SME stands for Small- and Medium-sized Enterprises. GRI follows the definition for SMEs as set by the European Union: SMEs have 250 employees or less and have a yearl
Publication Year 2013 GRI currently has two classifications for defining organization size: 'SME' and 'Large'. SME stands for Small- and Medium-sized Enterprises. GRI follows the definition for SMEs as set by the European Union: SMEs have 250 employees or less and have a yearl
Region NA Europe NA Region the organization operates in.
Report Html Address NA NA NA URL of the report location.
Report Pdf Address NA http://www.ono.es/resources/files/inversores/pdfs/ono_annual_report_2012.pdf NA Location of a PDF version of the report.
Report Title NA 2012 Annual Report NA Title of the report.
Sector NA Telecommunications NA Industry sector.
Sector Supplements (Final) NA Not Applicable NA This field indicates if the reporting organization has made use of one of the final Sector Supplements and which one. If ‘not used’ is indicated, it means that one of the final Sector Supplements is applicable, but has not been used. If ‘not applicable’ i
Size NA Large NA GRI currently has two classifications for defining organization size: 'SME' and 'Large'. SME stands for Small- and Medium-sized Enterprises. GRI follows the definition for SMEs as set by the European Union: SMEs have 250 employees or less and have a yearl

Flags

(Other Indicators - things that don’t affect ratings but that help identify or classify companies)

You have put report(s) in your cart
Go to my cart
Ok